The Latest Cardiac and Vascular News
Caristo’s CaRi-Heart® AI Technology used to monitor effects of Orticumab detected a reduction in coronary inflammation and predicted a 50% reduction in risk of fatal cardiac events among patients with high coronary artery inflammation ATLANTA, April 8, 2024 /PRNewswire/ — Abcentra LLC, a…
LOS ANGELES, Oct. 14, 2021 /PRNewswire/ — Abcentra LLC announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors. Dr. Davidson is currently CEO of New Amsterdam Pharma, and was previously the founding CEO and Chief Medical Officer of Corvidia Therapeutics, which was acquired by Novo-Nordisk in 2020. He also co-founded […]
LOS ANGELES, Aug. 4, 2021 /PRNewswire/ — Today, Abcentra LLC announced that the first patients have been dosed in its multi-center phase 2 trial assessing the safety and activity of orticumab in patients with moderate-to-severe plaque psoriasis and cardiometabolic risk factors. Orticumab is a fully-human monoclonal antibody against a specific oxidized low-density lipoprotein (LDL) epitope. Seventeen […]
SAN DIEGO, Sept. 17, 2019 /PRNewswire/ — Abcentra, a clinical-stage bio-pharmaceutical company that addresses unmet needs in inflammation, today announced its contribution to a 2019 study published in the American Heart Association Journals. The study found that, in those with high-cholesterol and major histocompatibility complex class II (MHCII) cells, treating atherosclerosis with immunotherapy […]
